About Us
Who We Are
Delphi: Your Go-To Psychedelic Consultancy
Led by Lia Mix, LMFT, CPTR, Delphi offers critical insights in the psychedelic ecosystem, to help propel your venture from pipeline to prominence with measured momentum. Our team of extraordinary advisors can help you reach goals strategically, ensuring accessibility for all.
As a leading authority in the psychedelic field, Delphi is known for integrity, wisdom, and an empowering approach. We navigate the complexities of psychedelics and healthcare, providing professional and empathetic guidance.
DELPHI delivers strategic insights and expert advice to diverse organizations, enhancing psychedelic-assisted therapy and mental health with evidence-based knowledge and progressive strategies.
Beyond sharing insights, we serve as trusted advisors within the psychedelic movement, offering elevated expertise and upholding the highest integrity standards. We are ready to collaborate to ensure your venture becomes a legacy in this transformative field.
Experts + Technology = Consensus + Coherent Messaging
What We Do
Areas of expertise
Delphi specializes in guiding and empowering leaders and organizations within the psychedelic space through strategic insights and expert consultancy.
Venture Capital & Investment
Delphi guides venture capitalists and financial entities through the financial landscape to secure funding, develop sustainable financial structures, and identify lucrative investment opportunities within the psychedelic space.
- VC Engagement: Engaging with venture capitalists to highlight lucrative opportunities.
- Funding Acquisition: Identifying and securing funding opportunities from investors and grants.
- Pitch Strategy: Crafting compelling pitches to attract investment and support.
- Financial Strategy: Developing strategic financial plans for investors in the psychedelic sector.
- 101 Education Series: Introductory course providing foundational knowledge about investment opportunities in psychedelics.
Pharma & Biotech
Delphi partners with pharmaceutical and biotechs to navigate the competitive landscape, ensure regulatory compliance, and foster collaborations with psychedelic research firms.
- Pharma Engagement: Mapping the psychedelic landscape and assessing competition.
- Funding Acquisition: Raising funds through detailed market analysis and healthcare economics.
- Communication Strategy: Crafting effective communication and branding strategies.
- Commercialization Strategy: Offering market insights, strategic planning, and Target Product Profile (TPP) development.
- 101 Education Series: Introductory course tailored for pharma and biotech professionals on psychedelic market opportunities.
Insurance Providers
Delphi collaborates with insurance providers to navigate reimbursement procedures, evaluate the cost-effectiveness of psychedelic therapies, and advocate for policy changes.
- Cost-Effectiveness Analysis: Conducting detailed analyses to demonstrate value.
- Payer Education: Educating insurers on access advocacy and sustainable healthcare.
- Healthcare Analytics: Providing decision analytics, outcome improvement, and healthcare innovation strategies.
- 101 Education Series: Introductory course tailored for insurance professionals on psychedelics in healthcare.
Governmental Bodies
Delphi provides industry insights that highlights real-world data on patient outcomes, and public health benefits of psychedelic therapies to help governmental bodies shape public health policy and implement strategies for integrating psychedelic therapies.
- Government Interface: Advising on policy engagement, governmental relations, and legislative progress.
- Policy Engagement: Guiding federal and state-level organizations in the psychedelic space.
- 101 Education Series: Introductory course tailored for governmental bodies on engaging with psychedelic developments.
Charitable Organizations
Delphi helps charitable organizations overcome barriers, identify impactful funding opportunities, and build networks to facilitate stakeholder consensus and collaboration within the psychedelic space.
- Stakeholder Engagement Planning: Developing network building, collaboration facilitation, and stakeholder consensus strategies.
- Collaboration Facilitation: Helping charitable organizations work effectively within the psychedelic ecosystem.
- Non-Profit Setup: Assisting in establishing non-profits, including finding fiscal sponsors and legal advisors.
- 101 Education Series: Introductory course tailored for charitable organizations on engaging with the psychedelic landscape.
Knowledge
integrates expertise
Knowledge
Our Work
Selected Projects
DELPHI has collaborated with a diverse array of organizations, including government agencies, venture capital firms, pharmaceutical and biotechnology companies, insurance providers, and charitable organizations.
Our expertise spans a wide array of disciplines across the psychedelic field, providing professional and empathetic guidance to foster meaningful connections and collaborations.
GOVERNMENT
PHARMA & BIOTECH
NON-PROFITS
DELPHI
Team
Our team consists of distinguished experts who will actively engage with clients, providing hands-on guidance and strategic oversight.
With diverse backgrounds in psychedelics, healthcare, and policy, they enhance our capability to deliver transformative, well-rounded, evidence-based solutions.
Data Analytics & Healthcare Economics
Desislava Prodanova
Community Engagement & Grant Writing
Martha Hammel
Professor of Medicine
Sylver Quevedo
Catalyzing Facilitator
Julia Mande
Healthcare Communications
Brian Mann
Healthcare Strategy, Innovation, and Growth Leader
Patrick Whitaker
Senior Medical Director
Joshua Lilienstein
Insurance Advisor
Adam Wilkins
Funding Strategy Lead
Lauren Tannhauser
For-Profit Strategy and Fundraising
Jake Hoskins
DELPHI
Executive Leadership
Our excecutive team comprises industry leaders and innovators dedicated to advancing the field of psychedelic consultancy.
Each member brings a wealth of expertise, ensuring that our strategic insights and guidance are rooted in both experience and a deep understanding of the psychedelic ecosystem.
Founder & CEO
Lia Mix
Lia has been instrumental in establishing the core infrastructure for integrating psychedelic-assisted therapy into the US healthcare system.